Abstract:Abstract Background: Primary tumor resection (PTR) in stage IV breast cancer (BC) patients currently lacks robust evidence supporting a prognostic benefit, and the guidelines do not actively endorse this practice. The circumstances under which patients may benefit from this procedure remain uncertain. Methods: The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program in the United States offers treatment data for stage IV breast cancer patients. We conducted a screening of patients diagnosed with metastatic breast cancer between 2010 and 2015. The primary outcomes focused on were overall survival (OS) and cancer-specific survival (CSS). We employed Kaplan-Meier method, Cox proportional hazard regression models, propensity score matching (PSM) to balance key confounding variables, and sequential landmark analyses to mitigate the impact of time-related factors on the results. Results : This study included 11,359 patients with stage IV breast cancer (BC). Patients who received primary tumor resection (PTR) experienced improved overall survival (OS) and cancer-specific survival (CSS). For OS (median survival time), the comparisons were as follows: chemoradiotherapy plus PTR versus chemoradiotherapy, with survival times of 56 months versus 25 months (p < 0.001); radiotherapy plus PTR versus radiotherapy, with survival times of 51 months versus 27 months (p < 0.001); chemotherapy plus PTR versus chemotherapy, with survival times of 45 months versus 32 months (p < 0.001); and only PTR versus no treatment, with survival times of 35 months versus 22 months (p < 0.001). Multivariate adjustment analysis, propensity score matching (PSM), and sequential landmark analyses provided further validation of these results. When stratified by different metastasis patterns, PTR significantly improved OS and CSS in patients with metastases in other organs, excluding brain metastasis. Regarding OS, the adjust hazard ratios (aHR) for different metastasis sites were as follows: bone metastasis (aHR0.555, 95% CI 0.514-0.598, p < 0.001); liver metastasis (aHR0.703, 95% CI 0.593-0.835, p < 0.001); brain metastasis (aHR0.639, 95% CI 0.549-0.734, p < 0.001); bone-liver metastasis (aHR0.716, 95% CI 0.601-0.852, p < 0.001); bone-lung metastasis (aHR0.782, 95% CI 0.667-0.915, p = 0.002); bone, liver, and lung metastasis (aHR0.712, 95% CI 0.550-0.921, p = 0.010). Notably, many patients with brain metastasis did not derive significant benefits from chemotherapy, and patients with liver metastasis saw improvements with radiotherapy alone. Similar conclusions were observed for cancer-specific survival (CSS). Conclusion: In patients with stage IV breast cancer, PTR in combination with chemotherapy or chemoradiotherapy can improve survival time. However, in cases of solitary brain metastasis and multiple metastases including brain metastasis, the decision to use PTR should be made with caution.

The Role of Primary Tumor Resection in Patients With Pancreatic Neuroendocrine Tumors With Liver Metastases

Role of Palliative Resection of the Primary Pancreatic Neuroendocrine Tumor in Patients with Unresectable Metastatic Liver Disease: a Systematic Review and Meta-Analysis

Surgical Resection of Primary Tumor Improves Survival of Pancreatic Neuroendocrine Tumor with Liver Metastases.

The Prognostic Impact of Primary Tumor Resection in Pancreatic Neuroendocrine Tumors with Synchronous Multifocal Liver Metastases.

Clinical Significance of the Preoperative Main Pancreatic Duct Dilation and Neutrophil-to-lymphocyte Ratio in Pancreatic Neuroendocrine Tumors (pnets) of the Head after Curative Resection

Outcomes of Primary Tumor Resection in Patients with Stage IV Pancreatic Neuroendocrine Neoplasms: A Population-Based Survival Analysis

Resection of Liver Metastases: A Treatment Provides a Long-Term Survival Benefit for Patients with Advanced Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis

Primary tumor resection enhances the survival of pancreatic neuroendocrine carcinoma patients with liver metastasis under the definition of 2019 WHO classification

Primary Tumor Resection for Rectal Cancer With Unresectable Liver Metastases: A Chance to Cut Is a Chance for Improved Survival

Impact of primary tumor resection in the management of metastatic well‐differentiated neuroendocrine tumors of the small bowel and pancreas

Do Patients Diagnosed with Metastatic Pancreatic Cancer Benefit from Primary Tumor Surgery? A Propensity-Adjusted, Population-Based Surveillance, Epidemiology and End Results (SEER) Analysis

Preoperative Chemotherapy Prior to Primary Tumor Resection for Asymptomatic Synchronous Unresectable Colorectal Liver-Limited Metastases: A Multicenter Randomized Controlled Trial.

Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients with Asymptomatic Primary Lesion and Synchronous Unresectable Metastases

Predicting Liver Metastasis in Pancreatic Neuroendocrine Tumor After Surgery: A Population-Based Study

The Value of Primary Tumor Resection among Different Treatment Methods in Stage IV Breast Cancer: Robust Evidence for Prognostic Benefit

Long-term Outcomes of Surgical Treatment for Pancreatic Neuroendocrine Neoplasm with Synchronous Hepatic Metastasis: A Multicenter Retrospective Cohort Study

Surgical Resection of a Primary Tumor Improves Survival of Metastatic Pancreatic Cancer: a Population-Based Study.

Clinical Analysis of Gastroenteropancreatic Neuroendocrine Tumor with Liver Metastasis, Compared with Primary Hepatic Neuroendocrine Tumor.

Primary Tumor Resection Provides Survival Benefits for Patients with Synchronous Brain Metastases from Colorectal Cancer

Palliative primary tumor resection may not offer survival benefits for patients with unresectable metastatic colorectal neuroendocrine neoplasms, one multicenter retrospective cohort study

Surgical resection of primary tumor is associated with prolonged survival in low-grade pancreatic neuroendocrine tumors